Age influences TSH serum levels after withdrawal of 1-thyroxine or rhTSH stimulation in patients affected by differentiated thyroid cancer

被引:19
作者
Montesano, Teresa
Durante, Cosimo
Attard, Marco
Crocetti, Umberto
Meningolo, Domenico
Bruno, Rocco
Tumino, Salvatore
Rubello, Domenico
Al-Nahhas, Adil
Colandlea, Marzia
Maranghi, Marianna
TravasCio, Laura
Ronga, Giuseppe
Torlontano, Massimo
机构
[1] Univ Roma La Sapienza, Dipartimento Sci Clim, I-00161 Rome, Italy
[2] Osped Cervello, Div Endocrinol, Palermo, Italy
[3] IRCCS, Div Endocrinol, San Giovanni Rotondo, Italy
[4] Osped Bentivoglio, Unita Operat Endocrinol, Bologna, Italy
[5] Osped Tinchi Pisticci, Div Endocrinol, Matera, Italy
[6] Univ Catania, Dipartimento Sci Biomed, Catania, Italy
[7] Osped Santa Maria Misericordia, Nucl Med Serv, Rovigo, Italy
[8] Hammersmith Hosp, Dept Nucl Med, London, England
关键词
rhTSH; thyroid cancer; follow-up; I-131; therapy; age;
D O I
10.1016/j.biopha.2007.04.001
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Recombinant human TSH (rhTSH) has been recently suggested for radioiodine ablation in patients with differentiated thyroid cancer (DTC). To date, studies are still not available about the effectiveness of rhTSH stimulation depending on the age, since serum TSH clearance may be different in younger and in older patients. The aim of this study was to investigate the influence of age to serum TSH levels after rhTSH stimulation and thyroid hormone withdrawal (THW). We retrospectively evaluated two groups of consecutive DTC patients: group 1 (311 patients, age 49.0 +/- 1 13.6 years, ranging 15-86) underwent rhTSH stimulation 6-12 months after thyroid ablation (rhTSH-group); group 2 (84 patients, age 46.9 +/- 13.5 years, ranging 20-77) was followed by THW (THW-group). The influence of age, gender, body mass index and body surface area to serum TSH levels were evaluated in both groups. RhTSH-group: on day 5 (0), TSH levels were 32.7 +/- 21.4 mu U/ml (range 0.8-136.6). By univariate analysis, d5-TSH was positively related to age (r = 0.27, p = 0.0001) and no correlations were found with the other parameters. At multivariate analysis, both age and gender (female) were independently associated with d5-TSH levels. THW-group: after thyroid hormone withdrawal, TSH levels were 71.1 +/- 36.4 mu U/ml (range 8.5-200). At univariate analysis, only age was significantly and negatively related to serum TSH levels (r = - 0.31, p = 0.004). Our data indicate that age and gender seem to positively influence serum TSH levels after rhTSH stimulation. An opposite effect of age on serum TSH levels has been observed after THW. Therapeutic implications ((131)-treatment) of these findings have to be better investigated in prospective studies. (c) 2007 Elsevier Masson SAS. All rights reserved.
引用
收藏
页码:468 / 471
页数:4
相关论文
共 13 条
[1]   Influence of human body composition on serum peak thyrotropin (TSH) after recombinant human TSH administration in patients with differentiated thyroid carcinoma [J].
Castagna, MG ;
Pinchera, A ;
Marsili, A ;
Giannetti, M ;
Molinaro, E ;
Fierabracci, P ;
Grasso, L ;
Pacini, F ;
Santini, F ;
Elisei, R .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2005, 90 (07) :4047-4050
[2]  
DUBOIS D, 1989, NUTRITION, V5, P303
[3]   A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer [J].
Haugen, BR ;
Pacini, F ;
Reiners, C ;
Schlumberger, M ;
Ladenson, PW ;
Sherman, SI ;
Cooper, DS ;
Graham, KE ;
Braverman, LE ;
Skarulis, MC ;
Davies, TF ;
DeGroot, LJ ;
Mazzaferri, EL ;
Daniels, GH ;
Ross, DS ;
Luster, M ;
Samuels, MH ;
Becker, DV ;
Maxon, HR ;
Cavalieri, RR ;
Spencer, CA ;
McEllin, K ;
Weintraub, BD ;
Ridgway, EC .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1999, 84 (11) :3877-3885
[4]   A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation [J].
Levey, AS ;
Bosch, JP ;
Lewis, JB ;
Greene, T ;
Rogers, N ;
Roth, D .
ANNALS OF INTERNAL MEDICINE, 1999, 130 (06) :461-+
[5]   Use of recombinant human thyrotropin before radioiodine therapy in patients with advanced differentiated thyroid carcinoma [J].
Luster, M ;
Lassmann, M ;
Haenscheid, H ;
Michalowski, U ;
Incerti, C ;
Reiners, C .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2000, 85 (10) :3640-3645
[6]   A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma [J].
Mazzaferri, EL ;
Robbins, RJ ;
Spencer, CA ;
Braverman, LE ;
Pacini, F ;
Wartofsky, L ;
Haugen, BR ;
Sherman, SI ;
Cooper, DS ;
Braunstein, GD ;
Lee, S ;
Davies, TF ;
Arafah, BM ;
Ladenson, PW ;
Pinchera, A .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2003, 88 (04) :1433-1441
[7]   DIAGNOSTIC USE OF RECOMBINANT HUMAN THYROTROPIN IN PATIENTS WITH THYROID-CARCINOMA (PHASE I/II STUDY) [J].
MEIER, CA ;
BRAVERMAN, LE ;
EBNER, SA ;
VERONIKIS, I ;
DANIELS, GH ;
ROSS, DS ;
DERASKA, DJ ;
DAVIES, TF ;
VALENTINE, M ;
DEGROOT, LJ ;
CURRAN, P ;
MCELLIN, K ;
REYNOLDS, J ;
ROBBINS, J ;
WEINTRAUB, BD .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1994, 78 (01) :188-196
[8]   Ablation of thyroid residues with 30 mCi 131I:: A comparison in thyroid cancer patients prepared with recombinant human TSH or thyroid hormone withdrawal [J].
Pacini, F ;
Molinaro, E ;
Castagna, MG ;
Lippi, F ;
Ceccarelli, C ;
Agate, L ;
Elisei, R ;
Pinchera, A .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2002, 87 (09) :4063-4068
[9]   The diagnostic use of the rhTSH/thyroglobulin test in differentiated thyroid cancer patients with persistent disease and low thyroglobulin levels [J].
Pellegriti, G ;
Scollo, C ;
Regalbuto, C ;
Attard, M ;
Marozzi, P ;
Vermiglio, F ;
Violi, MA ;
Cianci, M ;
Vigneri, R ;
Pezzino, V ;
Squatrito, S .
CLINICAL ENDOCRINOLOGY, 2003, 58 (05) :556-561
[10]   Recombinant human thyrotropin is a potent stimulator of thyroid function in normal subjects [J].
Ramirez, L ;
Braverman, LE ;
White, B ;
Emerson, CH .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1997, 82 (09) :2836-2839